Individualisation of immunosuppressant therapy in renal transplant recipients.

肾移植受者免疫抑制剂治疗的个体化。

• 批准号: nhmrc : 569784
• 负责人: Dr Katherine Barraclough
• 金额: $ 7.57万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/individualisation-immunosuppressant-therapy-transplant-recipients/116129
• 关键词: Individualisation; immunosuppressant; therapy; renal; transplant

People who undergo kidney transplantation require potent anti-rejection medications. Dosing is difficult. Two people given the same drug dose can have markedly different blood drug concentrations. If drug concentrations too low, there is an increased risk of rejection. If too high, there is an increased risk of drug side effects, infections and cancer. This study aims to find out why different people need different doses and to improve dosing methods, thereby improving patient outcomes.

接受肾移植的人需要有效的抗排斥药物。剂量是困难的。两个人给予相同的药物剂量可以有显着不同的血液药物浓度。如果药物浓度太低，排斥反应的风险会增加。如果太高，药物副作用，感染和癌症的风险增加。这项研究旨在找出为什么不同的人需要不同的剂量，并改进给药方法，从而改善患者的预后。